<DOC>
	<DOCNO>NCT00039494</DOCNO>
	<brief_summary>This pilot phase II trial study side effect best dose erlotinib give temozolomide radiation therapy see well work treat patient glioblastoma multiforme brain tumor . Radiation therapy use high-energy x-rays damage tumor cell . Erlotinib may interfere growth tumor cell , slow growth tumor , make tumor cell sensitive radiation therapy . Drugs use chemotherapy , temozolomide , work different way stop tumor cell divide stop grow die . Combining erlotinib temozolomide radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Erlotinib Temozolomide With Radiation Therapy Treating Patients With Glioblastoma Multiforme Other Brain Tumors</brief_title>
	<detailed_description>PILOT STUDY OBJECTIVES : I . Determine maximum tolerate dose erlotinib administer temozolomide radiotherapy patient glioblastoma multiforme grade 4 brain tumor currently enzyme-inducing anticonvulsant ( EIAC ) therapy v EIAC therapy . II . Determine safety tolerability regimen patient . III . Determine toxic effect regimen patient . IV . Determine efficacy regimen , term 1-year survival , patient . PHASE II OBJECTIVES : I . Determine response rate time progression patient treat regimen . II . Determine 6-month progression-free survival patient treat regimen . III . Determine toxic effect regimen patient . OUTLINE : This multicenter , dose-escalation pilot study erlotinib follow phase II study . Patients stratify accord concurrent enzyme-inducing anticonvulsant drug use ( yes v ) . PILOT STUDY : Patients receive oral erlotinib daily . After 1 week erlotinib alone , patient also receive oral temozolomide daily 6 week undergo concurrent radiotherapy 5 day week 6 week . After completion radiotherapy , patient continue receive erlotinib daily alone absence disease progression unacceptable toxicity . Beginning 4 week completion radiotherapy , patient also receive oral temozolomide daily 5 day . Temozolomide treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PHASE II : Once MTD erlotinib determine , additional patient treat erlotinib MTD , temozolomide , radiotherapy . Patients follow every 3 month 5 year annually 10 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm diagnosis 1 following : Glioblastoma multiforme ( grade 4 astrocytoma ) Gliosarcomas Other grade 4 astrocytoma variant ( e.g. , giant cell ) Must enrol least 1 week , 4 week , prior biopsy surgery Performance status ECOG 02 Performance status Karnofsky 60100 % At least 6 month Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin ≥ 9 g/dL Total bilirubin ≤ upper limit normal ( ULN ) AST great 2.5 time ULN Creatinine great 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No inability take oral medication No requirement IV alimentation No active uncontrolled peptic ulcer disease No abnormalities cornea ( e.g. , dry eye syndrome Sjögren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) No prior allergy intolerance dacarbazine No active malignancy require treatment No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior chemotherapy brain tumor No prior temozolomide No prior radiotherapy brain tumor No concurrent investigational agent More 21 day since prior major surgery ( exclude neurosurgical biopsy brain tumor resection ) No prior surgical procedure affect absorption No concurrent combination antiretroviral therapy HIVpositive patient No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>